Denali launches first commercial product AVLAYAH; Takeda exits DNL593 partnership

Filed May 7, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 6, 2025 · ~2 min read

Key Changes

• high

  AVLAYAH received FDA accelerated approval in March 2026 for Hunter syndrome neurologic manifestations and began commercial distribution in April 2026, marking Denali's transition from clinical-stage to revenue-generating company. Approval is contingent on confirmatory trial results.

  MD&A: AVLAYAH approval verify on EDGAR →
• high

  Takeda terminated the DNL593 (FTD-GRN) collaboration in April 2026, citing strategic considerations rather than safety or efficacy concerns. All rights revert to Denali, which now bears full development costs but retains full economic upside. Phase 1/2 data expected by end of 2026.

  MD&A: Takeda collaboration verify on EDGAR →
• high

  Royalty Pharma provided $200 million in March 2026 under a synthetic royalty agreement triggered by AVLAYAH approval. In exchange, Royalty Pharma receives 9.25% of worldwide net sales until cumulative royalties reach 2.5-3.0x funding received, reducing Denali's net revenue from the product.

  MD&A: Royalty financing verify on EDGAR →